Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix ™ Intranasal Antiviral Protection Against SARS-CoV-2 in Super Diffusion Event

Italy - Italian

NEWS PROVIDED BY
Nasus Pharma →
13 Oct, 2020, 2:11 pm BST

TEL AVIV , Israel, Oct.13 , 2020 / PRNewswire / - Nasus Pharma , a clinical-grade biopharmaceutical company developing a portfolio of intranasal powder-based (PBI) products targeting acute disease and public health threats, announced today data from a prospective survey of post-marketing users showing how Taffix ™, the innovative nasal powder inhaler that prevents viruses from reaching the nasal mucosa, was able to reduce the infection rate by at least 4 times from SARS-CoV-2 after a super diffusion event.

The Nasus user survey was conducted in Bney Brak, a city among the first in Israel for COVID-19 infection and mortality rate. Members of a synagogue were offered the use of Taffix, with instructions to use it when approaching a densely populated area. The poll was scheduled before Rosh haShana (the Jewish New Year), an event that involves prolonged periods of close proximity, at least 7 hours a day for 2 consecutive days, and which has

been called a super-diffusion event. Users and non-users among synagogue community members were monitored for up to 14 days after the event. The infection rate among non-users was 10% (16/160), while the infection rate among Taffix users was 2.4% (2/83 ITT, p = 0, 037) or 0% (0/81 PP p = 0.002). Over the same period of time, the overall infection rate in the city of Bney Brak increased by about 60%.

"These important results are consistent with previous in vitro studies conducted with Taffix ™ which demonstrated its valuable activity against the transmission of SARS-CoV-2," said Dr. Dalia Megiddo , CEO of Nasus Pharma. "This is the first real-life clinical finding to show that the use of Taffix is highly effective even in the worst-case scenario of a super-outbreak in the heart of Israel's worst-hit city. Reduce the risk of infection by 75% or even 100% can drastically change the resources available against the worst epidemic ever to hit humanity in about 100 years. "

Prof Y. Naparstek , of Hadassah Medical Center in Jerusalem , Israel, Scientific Director of the Meuhedet HMO Research Institute of Israel, added:

“The fact that Taffix has been able to significantly reduce the infection rate in users of the product is very encouraging. It can offer an additional layer of protection for those in situations that carry a high risk of infection. contribute to our knowledge of the effects on the protection of the population. Further controlled clinical trials will be needed to deepen our understanding of specific efficacy in different circumstances. "

Udi Gilboa , Executive Chairman of the Board of Directors of Nasus Pharma, added: "These promising clinical data support the potential role of Taffix ™ as an important solution and primary additional layer of protection, which will allow for the resumption of social and economic activities in much safer way.

In the global challenge of creating a new normal while living with the pandemic, we believe Taffix ™ can be an important clinically proven tool that offers an added measure of safety to our users and customers. Based on our very encouraging clinical results, we believe that Taffix, now available globally in many parts of the world, will be used on a daily basis in crowded environments (subway, trains, offices, supermarkets, airplanes, restaurants, etc.) and will be crucial as a personal protection, as well as being included in public health initiatives aimed at creating safer and more protected daily routines. "

Taffix ™ **,** currently approved for commercialization in Europe as a protective mechanical barrier against allergens and viruses (e.g. SARS-CoV-2) within the nasal cavity and in Israel as a block against inhalation of viruses and bacteria within the nasal cavity **,**was developed to create an acidic microenvironment in the nose, which has been shown to prevent viruses from entering and infecting nasal cells. There is growing evidence to suggest that the nose is the main gateway for viruses, including SARS-COV-2, with airborne droplet infection. Taffix ™ powder creates a unique thin layer of acidified gel above the nasal mucosa that lasts for 5 hours, significantly protecting nasal cells from inhaled viruses with both mechanical and chemical protection. Therefore Taffix could be an important new tool of protection for preventing SARS-COV-2 viral infections, in addition to the multiple preventive measures currently in use.

About Nasus Pharma:

Based on its unique bead technology, Nasus Pharma is developing a series of intranasal powder products aimed at assisting patients in various acute emergency situations such as opioid overdose and anaphylactic shock.

Intranasal administration is particularly suitable in situations where rapid administration is required and offers multiple advantages, such as rapid drug administration, ease of use, non-invasiveness and safety. Nasus' portfolio includes a number of programs: Intranasal Naloxone (for which Phase 3 is scheduled) and Intranasal Epinephrine (Phase 2), as well as a number of preclinical POC programs.

Contact:
Info@nasuspharma.com
Nasus Pharma Ltd. Israel

https://www.nasuspharma.com/

Logo - https://mma.prnewswire.com/media/1311013/Nasus_Pharma_Logo.jpg

SOURCE Nasus Pharma